The three major A-share indexes rose together, innovative drugs surged, STAR 50 fell over 2%, semiconductors adjusted, and YOFC hit the daily limit.
On July 15, A-shares fluctuated and rose in the morning session. Biopharmaceuticals exploded, with innovative drugs and CRO sectors surging. The liquor sector was active, while energy equipment and non-ferrous metals retreated. Semiconductor, advanced packaging, GPU and other concept stocks fell into adjustments, dragging the STAR 50 down by more than 2%.
Hong Kong stocks also fluctuated higher. Both the Hang Seng Index and Hang Seng Tech Index rose. Most technology internet stocks rebounded. AI large model stocks counterattacked, Zhipu rose nearly 10%, MINIMAX surged 14%. The biotech sector soared over 4%.
In the bond market, most treasury futures rose. In the commodities market, most domestic commodity futures rose. Core market movements:
A-shares: As of press time, the Shanghai Composite rose 0.15%, the Shenzhen Component Index rose 0.37%, and the ChiNext Index rose 0.61%.
Hong Kong stocks: As of press time, the Hang Seng Index rose 0.59%, and the Hang Seng Tech Index rose 0.01%.
Bonds: Treasury futures broadly fell. As of press time, the main 30-year contract rose 0.03%, the main 10-year and 5-year contracts were flat, and the main 2-year contract fell 0.01%.
Commodities: Domestic commodity futures mostly rose. As of press time, fuel oil rose nearly 5%, palladium and crude oil rose over 3%, asphalt and platinum rose 2%, Shanghai silver, Shanghai tin, rebar, pulp, and hot-rolled coil rose 1%. Iron ore, stainless steel, alumina, coking coal, Shanghai copper, coke, soybean meal, Shanghai gold, manganese silicon, rubber, lithium carbonate, rapeseed and other varieties all rose. A few varieties such as caustic soda, Shanghai aluminum, industrial silicon, shipping index, Shanghai nickel, glass, polysilicon, eggs, etc. fell.
10:26
The ChiNext Index rose over 1%.
10:05
The pharmaceutical sector continued to rise during the day. Innovative drugs and CXO led gains. Biovalley hit the 30cm limit-up. Previously, Harbin Pharmaceutical won four consecutive boards. Borui Pharma, Dizhe Pharma, Ruizhi Pharma, Hainan Haiyao, Baihua Pharma and others hit the limit-up. Deyuan Pharma, Wanbang Pharma, Changshan Pharma, Shiyao Innovation and many others rose over 10%.
09:56
Optical fiber concept stocks opened significantly higher. Yangtze Optical Fibre & Cable hit the limit-up. Guangku Technology, Changxin Bokuan, Yangtze Communications, Tongding Interconnection, Changying Tong and others followed upward.
On the news side, Yangtze Optical Fibre announced it expects net profit attributable to parent company in the first half of 2026 to be 2.4-3 billion yuan, a year-on-year increase of 711% to 914%. Benefiting from the accelerated construction of computing power data centers, domestic and international demand for new optical fiber and cable products continues to grow, and the industry’s supply-demand structure constantly improves. Against this backdrop, the company vigorously expanded business related to computing power data centers, achieved expansion of core customers, optimized product structure, and improved profitability.
09:43
Storage chip concept stocks fluctuated downward. Demingli hit limit-down, Bywei Storage fell over 8%, Dagang Holdings, Purang Holdings, Jia Bolong, and Langke Technology followed down.
On the news side, Demingli announced its net profit attributable to shareholders of the listed company for the first half of 2026 would be 5.7-6.5 billion yuan. The company’s Q2 net profit is expected to be 2.354-3.154 billion yuan, Q1 net profit is 3.346 billion yuan. According to this calculation, Q2 net profit is expected to fall 5%-29% quarter-on-quarter.
09:40
Computing power chip concept stocks weakened. Muxi Holdings fell nearly 10%. Moore Threads, Jingjia Micro, Lanqi Technology, Daxingda, Aojet Technology, and Cambricon followed down.
09:32
Innovative drugs repeatedly active. Harbin Pharmaceutical won four consecutive boards. Dizhe Pharma won two consecutive 20cm boards. Joincare New Drug touched the limit-up. Yinuosi, Shiyao Innovation, Ruizhi Pharma, Borui Pharma and others followed upward.
On the news side, the latest data disclosed by the National Medical Products Administration shows that from January to June this year, China reached 81 deals for external licensing of innovative drugs, with a total transaction value of about US$110 billion, already 80% of the total for 2025 and a new historical high.
At the same time, the NMPA disclosed that a total of 38 category 1 innovative drugs were approved for listing in the first half of this year, including 11 drugs with new targets or new mechanisms, all self-developed domestic innovative drugs.
09:26
The Shanghai Composite opened down 0.09%, the ChiNext rose 0.74%. Advanced packaging, semiconductor equipment, rare earth, lithography, PCB, cultivated diamonds, and memory concept stocks ranked among top gainers; oil and gas, commercial aerospace, traditional Chinese medicine, liquor, gold, and banks declined.
09:21
The Hang Seng Index opened up 0.87%, the Hang Seng Tech Index rose 0.78%. Zhipu rose over 6%, China Life rose over 4%, CATL and Lenovo Group rose over 3%.
Risk warning and disclaimerThe market has risks, investment needs to be cautious. This article does not constitute personal investment advice and has not taken into account the specific investment goals, financial situations or needs of individual users. Users should consider whether any opinions, viewpoints or conclusions given in this article are appropriate for their particular circumstances. Invest accordingly at your own risk.